JITC: Breakthrough!

In a new study, researchers from Tel Aviv University in Israel and the University of Lisbon in Portugal have discovered and synthesized a small molecule that could become an easier target than an antibody that has been successfully used to treat a range of cancers Obtained, more efficient alternative.

Professor Satchi-Fainaro said, “In 2018, the Nobel Prize in Medicine was awarded to James Allison and Tasuku Honjo for their contributions to the study of immunotherapy – the treatment of cancer by activating the immune syste.

Antibodies against PD-1/PD-L1 proteins have been approved for clinical use and are considered a great hope in the fight against cance.

In silico virtual screening of potential PD-1/PD-L1 inhibitor.

Professor Satchi-Fainaro said, "Postdoctoral researcher D.

In addition to drug accessibility considerations, the authors' experiments showed that the small-molecule drug improved the activation of immune cells within solid tumor masse.

Professor Satchi-Fainaro explained, "The surface of solid tumors is heterogeneou.

References:

Rita .